Can a drug combo turn back the clock on immune aging?

NCT ID NCT07363057

First seen Jan 24, 2026 · Last updated May 20, 2026 · Updated 21 times

Summary

This early-stage study tests whether a combination of two experimental drugs, GI-102 and GIB-7, can improve immune function and other signs of aging in healthy adults and cancer survivors. The trial involves 15 participants and lasts 8 weeks, focusing on safety and changes in immune cells like natural killer cells. It aims to address age-related immune decline, but ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ELDERLY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Novatrials

    RECRUITING

    Charlestown, New South Wales, 2290, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Southern Oncology Clinical Research Unit

    RECRUITING

    Adelaide, South Australia, 5042, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.